Introduction {#Sec1}
============

In recent years, therapeutic proteins have been a major focus of research and development activities in the pharmaceutical industry \[[@CR1]\]. Currently, approximately 100 therapeutic proteins have been approved for human use, most of them being biotechnology-derived drug products and many more are under development. Important classes of therapeutic proteins are monoclonal antibodies, growth factors, and cytokines. Generally, therapeutic proteins provide highly attractive but sometimes exceptional behavior in the body \[[@CR2]\]: their significant therapeutic potential results from their ability to bind---with high affinity---to specific targets such as receptors or cell surface proteins. For many protein drugs receptor mediated endocytosis (RME) is an important route of cellular uptake and disposition \[[@CR3]\]. RME is the process of binding of an endogenous or exogenous ligand to a receptor and subsequent internalization of the resulting complex forming an endosome. Within the cell, the complex may be recycled to the cell surface or intracellularly be cleaved \[[@CR4], [@CR5]\]. Receptor-mediated uptake plays a major role in the elimination of protein drugs from the body \[[@CR3]\] and is suspected to be a major source for the nonlinear pharmacokinetic (PK) behavior that is observed in clinical data for numerous protein drugs \[[@CR6]\].

When aiming at analyzing preclinical/clinical pharmacokinetic data of protein drug trials, typically *empirical* 1-, 2- or 3-compartmental models including linear and/or nonlinear disposition processes have been developed. Michaelis--Menten terms have often been used to analyze experimental data in order to account for the observed nonlinearity \[[@CR7]--[@CR11]\]. These models have been selected based on, e.g., established statistical criteria (such as maximum likelihood), the precision of estimates of model parameters, and in few cases on model evaluation techniques \[[@CR12]--[@CR15]\]. However, being empirical in nature, these models do not provide a mechanistic understanding of how the different processes of receptor trafficking contribute to the overall pharmacokinetic profile, which is expected to guide, e.g., lead optimization or the design of more efficient dosing regimens. Equally important, there is no theoretical background as to when use the different existing empirical models for nonlinearity.

Less often, models have been developed that also include mechanistic terms to account for nonlinear phenomena, most prominently in terms of target-mediated drug disposition (TMDD) models \[[@CR16]--[@CR18]\]. TMDD explicitly accounts for binding to a target and potential degradation of the resulting complex. Although originally developed to describe effects of extensive drug target binding in tissues, TMDD has more recently gained interest as a model for saturable elimination mechanisms for specific peptide and protein drugs, including RME \[[@CR6], [@CR18], [@CR19]\]. TMDD is a general approach for situations where the interaction of a drug with its target is considered to be relevant and might affect the concentration-time profiles. However, it does not explicitly take into account the particular features of receptor *trafficking* inside cells, such as recycling and sorting, i.e., the process by which receptors and ligands are either targeted for intracellular degradation or recycled to the surface for successive rounds of trafficking \[[@CR20]\].

There is a considerable amount of literature about detailed mechanistic descriptions of receptor trafficking systems in the systems biology literature (see, e.g., \[[@CR5], [@CR21]\] and references therein). Based on these receptor trafficking systems, our approach is to build a general detailed mechanistic model of RME that takes into account the most relevant kinetic processes of drug binding and receptor trafficking inside the cell. Detailed models derived from the underlying biochemical reaction network have the advantage of a mechanistic interpretation of the kinetic processes and estimated parameters. In \[[@CR22]\], a cell-level model of the cytokine granulocyte colony-stimulating factor (G-CSF) and its receptor was incorporated into a pharmacokinetic/pharmacodynamic model to allow for analyzing the life span and potency of the ligand in vivo. However, often these advantages come along with the disadvantage of containing more parameters which, e.g., in population PK analysis of clinal trials may result in poorer performance in the model selection process, since models containing more parameters are usually penalized by the corresponding model selection criteria.

The objective of this article is to develop a framework for RME that is specifically tailored to the needs in PK analysis of clinical trials by bridging the points of view in pharmacokinetics and systems biology. The aims are (i) to develop a detailed model that takes into account the most relevant processes in relation to receptor trafficking; (ii) to derive reduced models of RME which retain a mechanistic interpretation and are defined in terms of a few parameters only, (iii) to offer guidance as to when use them, and (iv) to analyze the impact of the different processes on the extent of nonlinearity. While our approach applies to many receptor systems in general, we will use the epidermal growth factor receptor (EGFR) signalling pathway to illustrate the approach. The EGFR system has been intensively studied over the past 20 years and is one of the most important pathways for cell growth and proliferation as well as angiogenesis and metastasis \[[@CR23]\]. The EGFR system comprises a tyrosine kinase receptor, which is activated by a variety of ligands such as the epidermal growth factor (EGF) or the transforming growth factor-α (TGF-α) \[[@CR24]--[@CR26]\]. Mathematical modelling of the EGFR system has proven to be useful for both, measurement of rate constants \[[@CR27]\] as well as to elucidate the effects of receptor trafficking as an input to downstream signalling cascades \[[@CR21], [@CR28]\]. From a therapeutic point of view, the EGFR system has shown to be a promising target in cancer therapy \[[@CR29], [@CR30]\]. Several agents, including therapeutic proteins such as monoclonal antibodies (mAbs), have been developed to specifically target the EGFR with some already approved for drug treatment \[[@CR31]--[@CR33]\].

Theoretical {#Sec2}
===========

Throughout the article, the term 'ligand' refers to both a physiological ligand as well as an exogenous drug ligand.

Detailed model of RME (Model A) {#Sec3}
-------------------------------

We propose the following detailed model of RME of a ligand as schematically represented in Fig. [1](#Fig1){ref-type="fig"}: the ligand *L*~ex~ is present in the extracellular space. The ligand reversibly binds to free receptor *R*~m~ at the cell membrane with association rate constant *k*~on~ to form the ligand--receptor complex *RL*~m~ that dissociates with rate constant *k*~off~. The complex is internalized with the rate constant *k*~interRL~ forming an endosome. The internalized ligand--receptor complex *RL*~i~ is either recycled to the membrane with the rate constant *k*~recyRL~, degraded with the rate constant *k*~degRL~ to*RL*~deg~, or dissociates with the rate constant *k*~break~. The dissociation results in the subsequent degradation of the ligand *L*~deg~ and the availability of the free receptor *R*~i~ inside the cell. Free intracellular receptor *R*~i~ is recycled to the membrane with the rate constant *k*~recyR~ and free membrane receptor *R*~m~ is internalized with the rate constant *k*~interR~. Inside the cell, the receptor *R*~i~ is produced with the rate *k*~synth~ and degraded with the rate constant *k*~degR~.Fig. 1Schematic representation of the detailed model of receptor mediated endocytosis. See text for description

Based on the law of mass action, the rates of change for the various molecular species are given by the following system of ordinary differential equations (ODEs): $$\documentclass[12pt]{minimal}
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Reduced models of RME {#Sec4}
---------------------

One objective of this study is to derive and analyze reduced models of RME that capture the impact of receptor dynamics on the distribution and elimination of a ligand and that still allow for a *mechanistic* interpretation. While during short time intervals the transient redistribution processes between the different receptor species *R*~m~, *RL*~m~, *RL*~i~ and *R*~i~ may be of interest, these are usually assumed to be negligible on time scales of interest in pharmacokinetics. Therefore, our approach to reduce the detailed RME model will be based on the assumption that the receptor species *R*~m~, *RL*~m~, *RL*~i~ and *R*~i~ are in quasi-steady state. In order to finally derive reduced models of RME, it is necessary to make an additional assumption on the time-scale of receptor synthesis and degradation. We distinguish the following two scenarios: (1) the time scale of receptor synthesis and degradation is *slow* in comparison to the time scale of ligand disposition. In this case, we formally set *k*~synth~ = *k*~degR~ = *k*~degRL~ = 0. As a consequence, the total number of receptors in the system remains constant. Or, (2) the time scale of receptor synthesis and degradation is *fast*, i.e., comparable to the redistribution processes of the different receptor species. Both scenarios will be used in the following to establish a link between the reduced and the detailed model.

### Reduced model of saturable distribution into the receptor system and linear degradation (Model B) {#Sec5}

The idea in deriving a reduced model of RME is to use the quasi-steady state assumption for the receptor system (RS). This transforms the differential equations ([2](#Equ2){ref-type=""})--([5](#Equ5){ref-type=""}) into algebraic equations for *R*~m~,*RL*~m~,*RL*~i~,*R*~i~. For a given number of extracellular ligand molecules *L*~ex~, these algebraic equations can be solved explicitly. This allows us to compute the total number of ligand molecules in the receptor system *L*~RS~ = *RL*~m~ + *RL*~i~ as a function of the extracellular number of ligands *L*~ex~. Based on *L*~RS~, the quasi-steady state number of intracellular ligand--receptor complexes *RL*~i~ can be computed, which determines the extent of elimination.

Model B (see Fig. [2](#Fig2){ref-type="fig"}) describes the evolution of the total number of ligands *L*~tot~ = *L*~ex~ + *L*~RS~ in form of the following ODE: $$\documentclass[12pt]{minimal}
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For the two scenarios of *slow* or *fast* receptor synthesis and degradation, the functional relation between the parameters *B*~max~, *K*~*M*~ and *k*~deg~ and the parameters of the detailed model of RME can be established. In the case of *slow* receptor synthesis and degradation, it is $$\documentclass[12pt]{minimal}
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### Reduced model of saturable degradation (Model C) {#Sec6}

The proposed Model C (see Fig. [2](#Fig2){ref-type="fig"}) is a further reduction of Model B. It is based on the additional assumption that the amount of ligand distributed into the receptor system is negligible in comparison to the total amount of ligand molecules, i.e., *L*~tot~ = *L*~ex~ + *L*~RS~ ≈ *L*~ex~. More formally, Model C can be derived from Model B under the assumption $$\documentclass[12pt]{minimal}
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Integration of RME into compartmental PK models {#Sec7}
-----------------------------------------------

In order to facilitate the transfer of reduced models of RME into compartmental PK models underlying PK data analysis and for use in the example of therapeutic protein receptor interaction, we explicitly state the system of ODEs for a two-compartment PK model. The model comprises a central compartment (volume *V*~1~ (in units volume) and ligand concentration *C*~1~ (in units mass/volume)) from which linear elimination CL~lin~ (in units volume/time) takes place and a peripheral compartment (volume *V*~2~ and total ligand concentration *C*~2~), where saturable elimination via receptor mediated endocytosis CL~RS~ takes place (see Fig. [3](#Fig3){ref-type="fig"}). In the peripheral compartment, we further distinguish between the concentration *C*~RS~ within the receptor system and the extracellular concentration *C*~ex~. The inter-compartmental transfer flows are denoted by *q*~12~ and *q*~21~ (in units volume/time).Fig. 3Two two-compartment models with linear clearance from the central compartment and RME based on Model B (left) and Model C (right) in the peripheral compartment

As in this article we are interested in how to represent RME in PK models, the below mentioned system of ODEs based on the reduced Models B and C represent the proposed structural PK model that can be used for parameter estimation in PK data analysis of nonclinical and clinical trials. The parameter values are determined by performing a fit of the model to the specific in vivo data. Alternatively, the model might be used to scale-up in vitro derived RME parameter values to the in vivo situation (see also [Discussion](#Sec17){ref-type="sec"}).

If Model B is used to describe the elimination by RME, the system of ODEs is $$\documentclass[12pt]{minimal}
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\begin{document}$$ C_{\rm ex} ={\frac{1}{2}}\left( C_2-B_{\rm max}-K_M + \sqrt{\left( C_2-B_{\rm max}-K_M \right)^{2}+4 K_M C_2} \right), $$\end{document}$$where dosing denotes a mass inflow (in units mass/time) of, e.g., an i.v. infusion over a given time. The parameter *B*~max~ denotes the total maximal ligand binding capacity in mass per volume or mol per volume, *K*~*M*~ denotes the concentration at which the binding capacity is half-maximal, CL~lin~ and CL~RS~ denote the total elimination capacities (in units volume/time) in the central and peripheral compartment, respectively. In terms of parameter estimation, the PK model contains eight parameters: *V*~1~, *V*~2~, *q*~12~, *q*~21~, CL~lin~, CL~RS~, *B*~max~ and *K*~*M*~, plus additional variables relating to dosing.

If Model C is used to describe the elimination by RME, the system of ODEs is $$\documentclass[12pt]{minimal}
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\begin{document}$$ V_2\cdot {\rm d} C_2/{\rm d} t = q_{12} \cdot C_1 - q_{21} \cdot C_2 - {\frac{V_{\rm max} \cdot C_2}{K_M + C_2}}, $$\end{document}$$where *V*~max~ denotes the total maximal elimination (in units mass/time), and all remaining parameters are defined as above. In terms of parameter estimation, the PK model contains seven parameters: *V*~1~, *V*~2~, *q*~12~, *q*~21~, CL~lin~, *V*~max~ and *K*~*M*~, in addition to the parameters relating to dosing.

Nonlinear PK caused by RME {#Sec8}
--------------------------

In this section, we investigate the extent of nonlinearity in the context of the Michaelis--Menten model defined in Eqs. [24](#Equ24){ref-type=""} and [25](#Equ25){ref-type=""}. We aim to examine the effect of drug and cell properties on the nonlinearity of the pharmacokinetics, e.g., different drug affinities to the receptor (different *k*~on~ and *k*~off~ values) or different rates of internalization and recycling of the drug in different cells.

In the chosen setting of the two-compartment PK model (cf. Eqs. [24](#Equ24){ref-type=""} and [25](#Equ25){ref-type=""}, the total clearance CL~tot~ is given by $$\documentclass[12pt]{minimal}
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In order to jointly analyze the *slow* and the *fast* receptor synthesis and degradation scenario, we set $$\documentclass[12pt]{minimal}
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It can be inferred from Table [1](#Tab1){ref-type="table"} that ligand-specific, receptor system-specific as well as mixed parameters influence the extent of nonlinearity of the PK: nonlinearity increases for higher affinity drugs (*k*~on~) and cell types, which have a higher receptor concentration at the surface of the cell membrane (*R*~0~, *k*~recyR~) and faster degradation processes (*k*~lyso~). In contrast, higher values of *k*~off~, *k*~recyRL~ and higher *k*~interR~, *k*~degR~ will decrease the extent of nonlinearity by resulting in a lower number of intracellular ligand receptor complexes, free receptor molecules, or a smaller number of receptor molecules at the cell surface membrane.Table 1Contribution of the different parameters to the extent of nonlinearityIncrease of parameterResulting change in extent of nonlinearity*R*~0~↑ (RS)*k*~recyR~↑ (RS)*k*~on~↑ (L)*k*~lyso~↑ (RS & L)*k*~interRL~↑ (RS & L)*k*~off~↓ (L)*k*~interR~↓ (RS)*k*~recyRL~↓ (RS & L)With increasing value of the corresponding parameter the extent of nonlinearity will increase (↑) or decrease (↓). For each parameter, it is indicated by (RS) or (L) whether it is related to the receptor system or the ligand, respectively

In order to more clearly highlight the contribution of the dissociation constant *K*~*D*~, we also give the following alternative representation of Eq. [28](#Equ28){ref-type=""}: $$\documentclass[12pt]{minimal}
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\begin{document}$$ {\frac{V_{\rm max}}{K_M}} ={\frac{R_{0}}{V_{\gamma} N_{A}}}\cdot {\frac{1}{K_D}} \cdot {\frac{1}{{\frac{1}{k_{\rm interRL}}}\left(1+{\frac{k_{\rm recyRL}}{k_{\rm lyso}}}\right)+{\frac{1}{k_{\rm off}}}}}\cdot \left( {\frac{1} {\left(1+{\frac{k_{\rm interR}}{k_{\rm recyR}}}\right)\left( {\frac{k_{\rm interR}}{k_{\rm recyR}}}\right)}}\right)^{p}. $$\end{document}$$As can be inferred from the above relation, the extent of nonlinearity can be very different for ligands with the same dissociation constant *K*~*D*~, but different absolute values of *k*~off~. The difference depends on the relative magnitude of the two terms in the first denominator in Eq. [29](#Equ29){ref-type=""}, i.e., 1/*k*~off~ to 1/*k*~interRL~ · (1 + *k*~recyRL~/*k*~lyso~).

Methods {#Sec9}
=======

In order to simulate Models A, B and C, we numerically solved the corresponding system of ODE's with Matlabs built-in ode15s integrator (The Mathworks, Inc., Natick/MA, USA, version 7.4). Parameter values for the reduced Models B and C were derived from those of Model A using the established relations (12)--(14), and (19) and (13), respectively. Subsequently, numbers of molecules where converted into concentrations (nM).

The models were compared based on the simulated extracellular drug concentration. The specific details of the simulation studies are given in the respective [Result](#Sec12){ref-type="sec"} section to allow for an easier comparison.

EGFR system with endogenous/physiological ligand {#Sec10}
------------------------------------------------

The application of our approach is illustrated using the EGFR system as an example. The properties of the EGF/EGFR system will be analyzed using experimentally measured parameters for the degradation of the epidermal growth factor, binding to the epidermal growth factor receptor and subsequent internalization \[[@CR20], [@CR34]\]. The rate constants of the corresponding reactions are listed in Table [2](#Tab2){ref-type="table"}.Table 2Parameter values for the EGF/EGFR systemParameterNumerical value*k*~on~5.82 1/(nM h)*k*~off~14.4 1/h*R*~m~^(*SS*)^2 × 10^5^ molecules*k*~recyR~3.84 1/h*k*~interR~4.2 1/h*k*~degR~0.96 1/h*k*~recyRL~1.2 1/h*k*~interRL~15 1/h*k*~degRL~1.2 1/h*V*~γ~4 × 10^−10^ 1/cellAll parameter values have been extracted from Hendriks et al. \[[@CR20], [@CR34]\] and Shankaran et al. \[[@CR28]\]. See also section "[RME for the EGF/EGFR system](#Sec13){ref-type="sec"}"

Hendriks et al. \[[@CR20], [@CR34]\] explored EGF as ligand to measure rate constants of the EGFR system. Since receptor is degraded as a consequence of ligand degradation, we choose the scenario of *fast* receptor synthesis and degradation for all investigations, i.e., Eqs. [12](#Equ12){ref-type=""}--[14](#Equ14){ref-type=""} and [19](#Equ19){ref-type=""}. However, not all rate constants of the herein proposed detailed model of RME were *explicitly* measured in \[[@CR20], [@CR34]\]. Since EGF is predominantly degraded from the EGF-receptor complex \[[@CR5]\] rather than from the free form, we set *k*~break~ = 0 resulting in *k*~lyso~ = *k*~degRL~ ≠ 0. Since the parameter *k*~synth~ was not available in literature, we used the steady state assumption for the receptor system prior to any ligand administration and the experimentally measured steady state number of membrane receptor *R*~m~^(*SS*)^ \[[@CR28]\] to determine *k*~synth~ using the relation *k*~synth~ = *k*~degR~ · *R*~i~^(*SS*)^ with *R*~i~^(*SS*)^ = *R*~m~^(*SS*)^ · *k*~interR~/*k*~recyR~. The initial number of receptors are *R*~m~(0) = *R*~m~^(*SS*)^, *R*~i~(0) = *R*~i~^(*SS*)^, and *RL*~m~(0) = *RL*~i~(0) = 0; the initial concentration of extracellular ligand is *L*~ex~(0) = 40 nM.

EGFR system with exogenous/therapeutic protein ligand {#Sec11}
-----------------------------------------------------

The analysis of drug-EGFR interaction are performed using data from the monoclonal antibody zalutumumab (2F8), as published by Lammerts van Bueren et al. \[[@CR11]\]. Zalutumumab is a human IgG1 EGFR antibody that potently inhibits tumor growth in xenograft models and has shown encouraging antitumor results in a phase I/II clinical trial \[[@CR35], [@CR36]\]. We transformed the originally published system of difference equations \[[@CR11], Supplement\] into the corresponding continuous system of ordinary differential equations[1](#Fn1){ref-type="fn"} (ODEs): $$\documentclass[12pt]{minimal}
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\begin{document}$$ \frac{\hbox{d}}{\hbox{d}t} A_{\rm b} = k_{\rm b} \left( \frac{\widehat{B}_{\rm max}(A_{\rm int}/V_{\rm int})^{h}}{ (A_{\rm int}/V_{\rm int})^{h}+ {K}_{\rm M}^{h}} - A_b \right) - \widehat{k}_{\rm deg} A_{\rm b}, $$\end{document}$$where *A*~pl~, *A*~int~ and *A*~b~ represent the amount of therapeutic protein in the plasma, interstitial and binding compartment, respectively; *V*~int~ the interstitial volume, *k*~pi~ and *k*~ip~ the rate constants for transfer between the plasma and interstitial compartment, *k*~b~ the rate constant for binding to and dissociation from EGFR, and *k*~el~ the elimination rate constant. Furthermore, $\documentclass[12pt]{minimal}
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\begin{document}$$\widehat{B}_{\rm max}/2$$\end{document}$, and *h* the Hill factor. The initial amount of drug *A*~pl~(0) and the parameters are listed in Table [3](#Tab3){ref-type="table"}. The reported value of *K*~M~ = 5 μg/ml did not allow us to reproduce the results in \[[@CR11], Fig.1A\]. Only a value of *K*~M~ = 0.5 μg/ml exactly reproduced the in silico data, hence we choose the corrected value for subsequent analyses. Amounts are converted to concentrations by dividing by the corresponding volume.Table 3Parameter values used by Lammerts van Bueren et al. \[[@CR11]\]ParameterNumerical value*V*~pl~35 ml/kg*V*~int~70 ml/kg$\documentclass[12pt]{minimal}
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\begin{document}$$\widehat{B}_{\rm max}$$\end{document}$2 mg/kg*k*~ip~0.043 1/h*k*~pi~0.043 1/h*k*~b~0.069 1/h*k*~*el*~0.0055 1/h$\documentclass[12pt]{minimal}
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\begin{document}$$ \widehat{k}_{\rm deg} $$\end{document}$0.005 1/h*K*~M~0.5 μg/ml*A*~pl~(0)2 and 20 mg/kg*h*1.0*K*~M~ has been corrected, see text for details. *V*~pl~ represents the plasma volume

Transforming the system of ODEs (30)--(32) from units \[mg/kg\] to \[mg/ml\] by dividing by the corresponding volumes yields equations for *C*~pl~ = *A*~pl~/*V*~pl~, *C*~int~ = *A*~*int*~/*V*~int~, *C*~b~ = *A*~b~/*V*~int~, in terms of the following scaled parameters *q*~12~ = *V*~pl~ · *k*~pi~, *q*~21~ = *V*~int~ · *k*~ip~, $\documentclass[12pt]{minimal}
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\begin{document}$$\hbox{CL}_{\rm lin}=k_{\rm el}\cdot V_{\rm pl}, B_{\rm max}=\widehat{B}_{\rm max}/V_{\rm int}, \hbox{CL}_{\rm RS}= \widehat{k}_{\rm deg} \cdot V_{\rm int}$$\end{document}$. The model (30)--(32) scaled to units \[mg/ml\] can be directly compared to our PK model (20)--(23) with *C*~1~ = *C*~pl~, *C*~ex~ = *C*~int~ and *C*~RS~ = *C*~b~, parameterized with the scaled parameters above. We remark that alternatively, our compartmental PK models could have been stated in units \[mg/kg\].

Results {#Sec12}
=======

RME for the EGF/EGFR system: an example for ligand--receptor interaction {#Sec13}
------------------------------------------------------------------------

For all subsequent in silico studies, the parameter values are stated as given in section "[EGFR system with endogenous/physiological ligand](#Sec10){ref-type="sec"}", unless stated otherwise.

### Influence of receptor system properties on RME {#Sec14}

We illustrate the approximation features of the two reduced models for predicting concentration-time profiles of the ligand in comparison to the detailed model based on the EGF/EGFR system. The initial concentration is *C*~ex~(0) = 40 nM. In Fig. [4](#Fig4){ref-type="fig"}(left), the predictions of the extracellular EGF concentration *C*~ex~ is shown for the three Models A, B and C. All models result in very similar concentration-time profiles: Almost instantaneously, the amount of ligand in the RS is in equilibrium. Due to the high concentration of ligand in comparison to the concentration of receptor, the RS is saturated and the ligand is eliminated at a constant rate. Between approximately 40-60 h, the system undergoes a transition from saturated to non-saturated elimination, which is manifested in the linear decline in the final phase (in the semi-logarithmic representation). For the EGF/EGFR system, the detailed model of RME is well approximated by Model B and also by Model C, the latter taking into account only the apparent saturable elimination. Based on the predictions of Model B, we computed the amount of ligand *L*~RS~ in the receptor system. In accordance with Eq. [15](#Equ15){ref-type=""}, *L*~RS~ is negligible in comparison to extracellular EGF concentration (cf. Fig. [5](#Fig5){ref-type="fig"}, solid line) while *C*~ex~ \> 0.01 nM.Fig. 4Concentration-time profile of the extracellular ligand concentration for the Model A (*circles* on blue solid line), Model B (*squares* on blue dashed line) and Model C (*diamonds* on red dashed line).*Left*: Parameter values used according to Table [2](#Tab2){ref-type="table"}.*Right*: As in left figure, but decreasing *k*~degRL~ 10-foldFig. 5Evolution of the ratio *B*~max~/(*K*~*M*~ + *C*~ex~) for the two scenarios shown in Fig. [4](#Fig4){ref-type="fig"} left (solid line) and right (dashed line)

In order to study the impact of *L*~RS~ on the approximation quality of Model C, we artificially decrease *k*~degRL~ by a factor of 10. All other parameters of the detailed Model A, including the initial EGF concentration, are identical. Parameters of Model B and C have been recalculated according to Eqs. [12](#Equ12){ref-type=""}--[14](#Equ14){ref-type=""} and Eqs. [19](#Equ19){ref-type=""} and [13](#Equ13){ref-type=""}, respectively, resulting in particular in an increased maximal binding capacity *B*~max~. The predictions of the concentration-time profile of the extracellular EGF concentration *C*~ex~ based on the three Models A, B and C are shown in Fig. [4](#Fig4){ref-type="fig"}(right). While Models A and B give almost identical results, the prediction based on Model C differs significantly. Model C over-predicts the extent of elimination by RME. As shown in Fig. [5](#Fig5){ref-type="fig"} the over-prediction corresponds to periods in time where the assumption (15) is violated: While *B*~max~/(*K*~*M*~ + *C*~ex~) is small for both settings up to time 60 h, it starts to increase thereafter, in particular for the setting corresponding to Fig. [4](#Fig4){ref-type="fig"}(right).

### Influence of different cell types on RME {#Sec15}

The detailed model A allows us to analyze the influence of processes on the overall disposition of ligand in the extracellular space such as, e.g., the ligand receptor internalization rate constant *k*~interRL~. Alterations in *k*~interRL~ have been observed experimentally \[[@CR37], [@CR38]\] and could be the result of a mutation of the EGF receptor. In view of Eq. [28](#Equ28){ref-type=""} we would expect a decrease in the overall elimination capacity with decreasing internalization rate constant *k*~interRL~. Figure [6](#Fig6){ref-type="fig"}(left) shows the impact of an altered *k*~interRL~ on the concentration-time course of EGF with *C*~ex~(0) = 40 nM. As can be seen, cells with a reduced internalization rate constant *k*~interRL~/4 and *k*~interRL~/16 show a much lower apparent elimination than the reference cells with the rate constant *k*~interRL~. The difference in the apparent elimination does not only depend on the absolute magnitude of change of *k*~interRL~, but more precisely on the magnitude of change of 1/*k*~interRL~ · (1 + *k*~recyRL~/*k*~lyso~) in relation to 1/*k*~off~, as can been inferred from Eq. [29](#Equ29){ref-type=""}. Changes in *k*~interRL~ will have less impact, if 1/*k*~off~ is large. This can be seen in Fig. [6](#Fig6){ref-type="fig"}(right), which shows the same situation as in the left figure, but with *k*~off~ decreased by a factor of 100 (we also decreased *k*~on~ by the same factor in order to keep *K*~*D*~ constant).Fig. 6Illustration of the dependence of RME on the rate of internalization using the detailed model of RME (Model A). Parameter values according to Table [2](#Tab2){ref-type="table"}.*Left*: concentration-time profiles of the extracellular ligand EGF (*L*~ex~) for three different internalization rate constants of the ligand--receptor complex: *k*~interRL~ (*solid line*), *k*~interRL~/4 (*dashed line*), *k*~interRL~/16 (*dotted line*).*Right*: same as before, but with decreased association and dissociation rate constants: *k*~on~/100 and *k*~off~/100, respectively. Note that *K*~*D*~ is identical in the left and right graphics

RME in the monoclonal antibody/EGFR system: an example for therapeutic protein--receptor interaction {#Sec16}
----------------------------------------------------------------------------------------------------

In this section we will illustrate how our unified theoretical approach to RME allows for resolving seemingly contradictory statements about the performance of empirical models of RME. In \[[@CR11]\], Lammerts van Bueren et al. reported about a preclinical study involving a mAb against EGFR in monkeys and their subsequent data analysis. They developed a two-compartment pharmacokinetic model comprising a first-order elimination of the mAb from plasma, a binding compartment (representing EGFR-expressing cells) that equilibrates with the interstitial compartment, and a saturable internalization and degradation of bound mAb. For a detailed description of the model and the corresponding parameters see section "[EGFR system with exogenous/therapeutic protein ligand](#Sec11){ref-type="sec"}". Lammerts van Bueren et al. concluded that the observed nonlinear decrease of mAb concentrations in cynomolgus monkeys could not be explained by a saturable elimination in terms of a Michaelis--Menten model and proposed an alternative model, which described the data well. In a different study, the Michaelis--Menten model was reported to successfully describe in vivo data for a monoclonal antibody \[[@CR10]\].

The model proposed in \[[@CR11]\] is comparable to the two-compartment model introduced in the section "[Integration of RME into compartmental PK models](#Sec7){ref-type="sec"}", Eqs. [20](#Equ20){ref-type=""}--[23](#Equ23){ref-type=""}. In order to understand the inferences made by Lammerts van Bueren et al. \[[@CR11]\], we simulated their model defined in Eqs. [30](#Equ30){ref-type=""}--[32](#Equ32){ref-type=""} and compared the results to the correspondingly parameterized Models B and C (see Fig. [7](#Fig7){ref-type="fig"}, left). Since the experimental data presented in \[[@CR11]\] were not available and since model simulations and data were reported to be in good agreement, we used the Lammerts van Bueren model as a surrogate for the experimental data. As in \[[@CR11]\], we choose a high and low initial mAb input of 2 and 20 mg/kg. While the predicted mAb plasma concentrations based on Model B are identical to the prediction based on the Lammerts van Bueren et al. model, predictions based on Model C deviate significantly. A closer inspection reveals that the assumption *B*~max~/(*K*~*M*~ + *C*~ex~(0)) ≪ 1 is violated for the low dose of 2 mg/kg. Consequently, the amount of mAb inside the RS cannot be neglected and we would expect to see deviations between predictions based on Models B and C. Hence, the use of a Michaelis--Menten based nonlinear elimination in the interstitial compartment, which neglects the drug distributed into the receptor system, leads to an over-prediction of drug elimination by RME (see Fig. [7](#Fig7){ref-type="fig"}, left).Fig. 7Comparison of model predictions for zalutumumab (2F8) based on the Lammerts van Bueren et al. model (circles on solid line) and the herein proposed compartment models (20)--(23) (*squares* on solid line) and (24)-(25) (*diamonds* on dotted line).*Left*: parameterization as given in Table [3](#Tab3){ref-type="table"}.*Right*: maximal receptor capacity *B*~max~ decreased to one 20th of the original capacity

The difference between the predictions based on Model B and C should disappear, if the maximal binding capacity is sufficiently decreased. This is shown in Fig. [7](#Fig7){ref-type="fig"}(right), where the binding capacity *B*~max~ has been decreased to one 20th of its original value.

In summary, the inference made in \[[@CR11]\] that a Michaelis--Menten term is not adequate for modeling the nonlinearity present in the data is valid for the specific conditions of their experimental design. However, this cannot be generalized to a statement about the validity of the Michael-Menten approximation of RME, as can be seen from Fig. [7](#Fig7){ref-type="fig"}(right) and also from the results presented in section "[RME for the EGF/EGFR system](#Sec13){ref-type="sec"}".

Discussion {#Sec17}
==========

Drugs that demonstrate nonlinear pharmacokinetic behavior at therapeutic concentrations often cause difficulties in designing dosage regimens and determining relations between drug concentrations and effects. The theoretical bases and potential causes of nonlinear/dose-dependent pharmacokinetics are many-fold and have been extensively reviewed (see \[[@CR17]\] and reference therein). Therapeutic proteins bind with high affinity to specific targets. For many protein drugs elimination by RME plays a major role in their elimination from the body \[[@CR3]\]. RME is suspected to be a major source for the nonlinear pharmacokinetic behavior that is observed in pre-/clinical data of numerous protein drugs \[[@CR6]\]. In this article we theoretically investigated the process of RME on the pharmacokinetics of therapeutic proteins.

The detailed Model A (see Fig. [1](#Fig1){ref-type="fig"}) represents RME for an endogenous compound in terms of a system of biochemical reactions (1)--(5), including the binding of the ligand to the receptor, subsequent internalization of the complex and eventually degradation as well as receptor recycling, degradation and synthesis. Two reduced models have been derived under the assumption that the redistribution processes between the receptor species *R*~m~, *RL*~m~, *R*~i~ and *RL*~i~ are in quasi-steady-state. For the EGFR system, this assumption has been shown experimentally \[[@CR27]\]. For other receptor systems, the steady state assumption seems reasonable since intracellular processes are typically much faster than the time scale of interest in pharmacokinetic studies.

With respect to the pharmacokinetics of therapeutic proteins, two aspects of RME are of particular importance: Distribution as a consequence of the drug binding to the receptor and subsequent internalization of the complex; andElimination as a consequence of endocytosis.

Unfortunately both processes typically cannot be differentiated experimentally in pharmacokinetics. Model B explicitly takes into account the amount of drug *L*~RS~ distributed in the receptor system and the elimination by intracellular degradation, e.g., lysosomes. While the elimination is a linear process in terms of *L*~RS~, the distribution into the receptor system itself is a saturable process, specified in terms of *B*~max~ and *K*~*M*~. Model C is derived from model B by assuming in addition that *L*~RS~ is negligible in comparison to the extracellular amount *L*~ex~. In view of the above two sub-processes, this is equivalent to the assumption that the distributional aspect of RME can be neglected. Notably, even if the distributional aspect is negligible, the receptor system could still very efficiently transport ligand molecules into the cell, where they are subsequently degraded. This can be explained from Eq. [17](#Equ17){ref-type=""}. It states that the maximal elimination rate *V*~max~ is the product of the maximal ligand binding capacity *B*~max~ and the degradation rate constant *k*~deg~. The maximal elimination rate *V*~max~ may still be large due to a large *k*~deg~, even if *B*~max~ is small. The latter implies a negligible amount of ligand *L*~RS~ within the receptor system. The receptor system acts as a mechanism that transports ligand molecules into the cell to eventually degrade them. Whether or not the receptor system also serves as a distribution phase is independent from the elimination aspect. This yields the following guidance for the usage of the two reduced models: *Model B*: Elimination *and* distribution of ligand into the receptor system are important processes to be considered.*Model C*: The distribution of ligand into the receptor system can be neglected, only the elimination process is important, which in this case is non-linear.

Based on Model B and the computable criterion (15) it can easily be checked whether the condition for the applicability of Model C are fulfilled. This has been demonstrated for the EGF/EGFR system in section "[RME for the EGF/EGFR system](#Sec13){ref-type="sec"}", see Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}.

The reduced models are derived under the quasi-steady state assumption that the receptor redistribution processes are much faster than the ligand pharmacokinetics. This assumption is of the same type as the assumption underlying the Michaelis--Menten model of enzyme reactions, where it is assumed that the complex formation, dissociation and catalytic transformation are much faster than the transformation of substrate into product. In order to finally derive reduced models, we have to make an additional assumption on the time-scale of receptor synthesis and degradation. There are three different scenarios: receptor synthesis and degradation is (i) as fast as receptor redistribution (or faster); (ii) slower than the time scale of ligand pharmacokinetics; or (iii) at an intermediate time scale, i.e., comparable or faster than ligand PK but slower than receptor redistribution. The first two scenarios correspond to our *fast* and *slow* scenario. Under these assumptions it is possible to either treat receptor synthesis and degradation the same way as the redistribution processes (in the *fast* scenario) or neglect it and treat the total amount of receptor as a constant (in the *slow* scenario), since in the latter it would not impact the total number of receptors on the time scale of interest. In the third scenario, however, receptor synthesis and degradation would need to be taken into account in terms of an additional ODE. Unless further assumptions are made, this would require to consider the full system of Eqs. [1](#Equ1){ref-type=""}--[5](#Equ5){ref-type=""}---which is not suitable for PK parameter estimation in clinical trials.

The elimination process of RME is specified in terms of the parameters *V*~max~ and *K*~*M*~. Noteworthy, the maximal elimination rate *V*~max~ is *independent* of the processes of complex formation (*k*~on~) and dissociation (*k*~off~) of the receptor-ligand complex. However, the parameters *k*~on~ and *k*~off~ influence the amount of extracellular ligand molecules *K*~*M*~, at which the elimination rate is half-maximal.

In Fig. [6](#Fig6){ref-type="fig"}, we studied the impact of different internalization rate constants *k*~interRL~ on RME. An altered *k*~interRL~ could, e.g., result from a mutation in the EGF receptor, as it has been observed experimentally \[[@CR37]\]. Our analysis in section "[Nonlinear PK caused by RME](#Sec8){ref-type="sec"}" shows that the ligand elimination rate is affected by various processes inside the cell. For example, the elimination rate decreases with decreasing complex internalization rate constant, but the difference is much less pronounced for a ligand with decreased association and dissociation rate constants *k*~on~ and *k*~off~---even though the dissociation constant *K*~*D*~ is the same in both scenarios (see Fig. [6](#Fig6){ref-type="fig"}, left vs. right). From the detailed Model A, this phenomenon is understandable: given a ligand that forms a complex with rate constant *k*~on~, once the ligand--receptor complex is formed at the membrane, its fate is a balance between dissociation (specified in terms of *k*~off~) and internalization (specified in terms of *k*~interRL~). If, e.g., *k*~off~/*k*~interRL~ ≪ 1 then the complex will predominantly be internalized. Based on *K*~*D*~ alone, this property of receptor systems can not be observed. The ratio *k*~off~/*k*~interRL~ has recently been introduced as one of two key parameters to characterize different cell surface receptor systems (termed the consumption parameter) \[[@CR28]\]. In general, our analysis shows that reduced ligand elimination from the extracellular space can be due to altered processes inside the cell other than the velocity of internalization of the complex. The influences of the processes can be deduced from Eq. [28](#Equ28){ref-type=""} and is summarized in Table [1](#Tab1){ref-type="table"}. The nonlinearity increases with parameters that accelerate' the processes of receptor availability at the surface (*R*~0~, *k*~recyR~) or that accelerate' the transport and intracellular degradation of extracellular ligand (*k*~on~, *k*~interRL~, *k*~lyso~). Counteracting processes (related to the parameters *k*~off~, *k*~interR~, *k*~recyRL~) decrease the extent of nonlinearity.

Target-mediated drug disposition (TMDD) models explicitly account for binding to a target and potential degradation of the resulting complex \[[@CR16]--[@CR18]\]. Although originally developed to describe effects of extensive drug target binding in tissues, TMDD has more recently also gained interest as a model of saturable elimination mechanisms for specific peptide and protein drugs, including RME \[[@CR6], [@CR18], [@CR19]\]. Between TMDD and the herein presented approach, there are a number of distinct differences. First, the TMDD approach considers pharmacological target binding as the key process controlling the complex nonlinear processes. Particular features of receptor *trafficking* inside the cell are not taken into account. Second, whenever a drug molecule is degraded in the TMDD setting, both, a drug and a receptor molecule are degraded. In the herein presented approach, degradation of the drug does not necessarily imply degradation of the receptor, since the receptor can be recycled. This is, e.g., an important characteristics for the ligand TNF-α. Third, in \[[@CR16]\], a reduced model of TMDD is presented based on a equilibrium assumption. In this reduced TMDD model, the unbound extracellular drug concentration is a function of the total concentration, the total receptor concentration *R*~tot~ and the *equilibrium* dissociation constant *K*~*D*~ \[[@CR16], Eq. 11\]. In our reduced model B, in contrast, the extracellular drug concentration is a function of the total concentration, the maximal receptor binding capacity *B*~max~ and the *quasi-steady state* parameter *K*~*M*~ (cf. Eq. [8](#Equ8){ref-type=""}). As a consequence, the models make qualitatively different predictions. For instance, *K*~*M*~ does not only depend on the ratio of *k*~off~ and *k*~on~ (i.e., *K*~*D*~), but also on the actual magnitude of the two parameters, in addition to the dependence on receptor systems parameters. This implies that two drugs with the same *K*~*D*~ but different *k*~off~ values might be impacted by RME very differently. This has been illustrated in Fig. [6](#Fig6){ref-type="fig"} (compare left and right graphics) and discussed above.

If the reduced models of RME are used as part of structural PK models to estimate parameters in the course of clinical data analysis, the question arises whether or not the identified RME parameters *B*~max~, *K*~*M*~, *k*~deg~ and *V*~max~ allow for a mechanistic interpretation, e.g., whether *B*~max~ can be interpreted as the maximal RME ligand binding capacity. This question is tightly linked to the question of identifiability of model parameters, sometimes referred to as the inverse problem. Identifiability has been studied in detail in the context of compartmental models (see, e.g., \[[@CR39], Chap. 5--9\]). In general, the identifiability of model parameters depends on the structural model (number of compartments, compartment to which the RME process is linked, existence of additional routes of elimination, etc.), prior knowledge of model parameters and the quality of the experimental design \[[@CR39], Chap. 5\]. To illustrate this, we used the detailed model to generate a set of simulated data, to which we fitted the reduced Models B and C (data not shown). We found that for a well-designed experiment (i) the estimated parameters of the reduced RME models obey the expected relations (12)--(14) and (19); (ii) that Model C will not result in a good fit, if the condition *B*~max~/(*K*~*M*~ + *L*~ex~) ≪ 1 is violated. This was the case for the in vitro data shown in Fig. [4](#Fig4){ref-type="fig"}(left), as well as for the in vivo data shown in Fig. [7](#Fig7){ref-type="fig"}(left), where already the authors in \[[@CR11]\] reported that they were not able to fit a Michaelis--Menten based PK model to the experimental data. However, if the experimental design is not adequate, then we would expect---in accordance with the parameter identifiability problem \[[@CR39], Chap. 5--9\]---that the above conditions (i) and/or (ii) are violated. This was the case for the in vitro data shown in Fig. [4](#Fig4){ref-type="fig"}(right), where both Model B and Model C could be fitted to the generated data based on Model A, although the condition *B*~max~/(*K*~*M*~ + *L*~ex~) ≪ 1 was violated (resulting in deviation of the estimated parameters from the expected parameters of 6−20% for Model B and 500% for Model C). Since the criteria in Eq. [15](#Equ15){ref-type=""} has not been met, the violation of relations in Eqs. [19](#Equ19){ref-type=""} and [13](#Equ13){ref-type=""} for Model C is in accordance with our expectations. Furthermore, for the situation corresponding to Fig. [4](#Fig4){ref-type="fig"}(right), the expected relation *V*~max~ = *k*~deg~ · *B*~max~ (see Eq. [17](#Equ17){ref-type=""}) was violated, while it was satisfied for the situation corresponding to Fig. [7](#Fig7){ref-type="fig"}(left). These results eventually motivate the following recommendation:*Consistency check*: Use both reduced Models B and C to fit the data and check the two conditions (15) and (17): $$\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ \frac{B_{\rm max}} {K_M + L_{\rm ex}} \ll 1\quad \hbox{and}\quad V_{\rm max}=k_{\rm deg}\cdot B_{\rm max}. $$\end{document}$$A violation of the conditions might indicate an insufficient experimental design, and/or insufficient convergence of the fitting algorithm (local minimum).

Different empirical models have been proposed and used to model the nonlinear pharmacokinetics of therapeutic proteins \[[@CR7]--[@CR15]\]. While, e.g., a Michaelis--Menten based RME model as part of a PK model allowed for describing data in one PK data analysis (e.g., \[[@CR10]\]), it failed to do so in another (e.g., \[[@CR11]\]). Due to lack of a sound theoretical basis to understand the different performances of empirical models, this certainly was an unsatisfactory situation. The herein presented analysis gives a thorough background of RME and a clear rationale as to when the proposed reduced models are applicable. In addition, the functional relations between the parameters of the detailed Model A and the reduced Models B and C might also serve as a first step to scale in vitro observations on RME to in vivo predictions of either target mediated disposition or Michaelis--Menten elimination, dependent upon the expression level and turnover of the target.
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The originally published equations in \[[@CR11], Supplement\] are identical to a certain discretization of the system of ODEs (30)--(32). The advantage of stating the system as continuous ODEs is that subsequently any numerical scheme can be used to solve them, in particular high accuracy ODE solver with adaptive step size control.
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